Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Qiong Yi, GuangYao Wang, ZongXiang Yue
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
von: Eunice Yewon Lee, et al.
Veröffentlicht: (2024)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
von: Muhammad Osama, et al.
Veröffentlicht: (2024)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
von: Wah Loong Chan, et al.
Veröffentlicht: (2024)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease
von: Derek D. Satre, et al.
Veröffentlicht: (2024)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
von: Rong‐Xiang Ng, et al.
Veröffentlicht: (2025)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
von: Seren Gedallovich, et al.
Veröffentlicht: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
von: Ryan Yanzhe Lim, et al.
Veröffentlicht: (2026)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
von: Mathias Jachs, et al.
Veröffentlicht: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Stergios A. Polyzos, et al.
Veröffentlicht: (2024)

Disparities in Alcohol‐Associated Liver Disease Hospital Encounters Amongst a Texas‐Based Cohort of Patients
von: Thomas G. Cotter, et al.
Veröffentlicht: (2025)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
von: Chunlong Liu, et al.
Veröffentlicht: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
von: Finlay Macrae
Veröffentlicht: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
von: Juan Macias, et al.
Veröffentlicht: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
von: Xinglin Li, et al.
Veröffentlicht: (2026)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
von: Paul Y. Kwo, et al.
Veröffentlicht: (2026)

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
von: Benedikt Simbrunner, et al.
Veröffentlicht: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
von: Kaleb Tesfai, et al.
Veröffentlicht: (2026)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis?
von: Alessandro Granito, et al.
Veröffentlicht: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
von: Karen Cheuk‐Ying Ho, et al.
Veröffentlicht: (2025)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
von: YaoYao Dai, et al.
Veröffentlicht: (2025)

Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
von: Xing Bai, et al.
Veröffentlicht: (2025)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
von: Merle Claßen, et al.
Veröffentlicht: (2024)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2025)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
von: Ming Liu, et al.
Veröffentlicht: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
von: Dong Hyun Kim, et al.
Veröffentlicht: (2025)

Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”
von: Ersel Bilgin, et al.
Veröffentlicht: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
von: Jee‐Fu Huang, et al.
Veröffentlicht: (2026)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
von: Jia‐Yong Su, et al.
Veröffentlicht: (2025)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
von: Zhanbo Qu
Veröffentlicht: (2026)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
von: Luis Antonio Díaz, et al.
Veröffentlicht: (2025)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Gian Paolo Caviglia, et al.
Veröffentlicht: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
von: Ning Yu, et al.
Veröffentlicht: (2025)

Editorial: ICG ‐ R15 by PDD —A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease
von: Yixuan Zhu, et al.
Veröffentlicht: (2025)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
von: Glenn Jun Kit Ho, et al.
Veröffentlicht: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
von: Sai Kiran Kuchana, et al.
Veröffentlicht: (2026)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
von: Pojsakorn Danpanichkul, et al.
Veröffentlicht: (2025)